QGEN vs. RGEN, PCVX, TECH, RVMD, NBIX, EXEL, HALO, KRYS, IBRX, and CRSP
Should you be buying Qiagen stock or one of its competitors? The main competitors of Qiagen include Repligen (RGEN), Vaxcyte (PCVX), Bio-Techne (TECH), Revolution Medicines (RVMD), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Halozyme Therapeutics (HALO), Krystal Biotech (KRYS), ImmunityBio (IBRX), and CRISPR Therapeutics (CRSP). These companies are all part of the "biological products, except diagnostic" industry.
Repligen (NASDAQ:RGEN) and Qiagen (NYSE:QGEN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, community ranking, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.
Repligen currently has a consensus price target of $197.75, suggesting a potential upside of 27.85%. Qiagen has a consensus price target of $50.95, suggesting a potential upside of 18.26%. Given Qiagen's stronger consensus rating and higher probable upside, equities analysts plainly believe Repligen is more favorable than Qiagen.
In the previous week, Repligen had 9 more articles in the media than Qiagen. MarketBeat recorded 21 mentions for Repligen and 12 mentions for Qiagen. Qiagen's average media sentiment score of 0.73 beat Repligen's score of 0.50 indicating that Repligen is being referred to more favorably in the media.
97.6% of Repligen shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 1.2% of Repligen shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Qiagen has a net margin of 17.38% compared to Qiagen's net margin of 2.44%. Repligen's return on equity of 12.59% beat Qiagen's return on equity.
Repligen received 156 more outperform votes than Qiagen when rated by MarketBeat users. Likewise, 68.08% of users gave Repligen an outperform vote while only 60.79% of users gave Qiagen an outperform vote.
Repligen has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.42, meaning that its stock price is 58% less volatile than the S&P 500.
Qiagen has higher revenue and earnings than Repligen. Qiagen is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.
Summary
Repligen beats Qiagen on 11 of the 18 factors compared between the two stocks.
Get Qiagen News Delivered to You Automatically
Sign up to receive the latest news and ratings for QGEN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding QGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
